BioCryst Pharmaceuticals, Inc. (BCRX)
USD 6.55
(-4.1%)
USD 6.55
(-4.1%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 430.64 Million USD | 3.91% |
| 2022 | 412.66 Million USD | 25.96% |
| 2021 | 327.62 Million USD | 71.63% |
| 2020 | 190.89 Million USD | 32.39% |
| 2019 | 144.18 Million USD | 26.04% |
| 2018 | 114.4 Million USD | 41.42% |
| 2017 | 80.89 Million USD | 11.95% |
| 2016 | 72.26 Million USD | -15.78% |
| 2015 | 85.8 Million USD | 44.8% |
| 2014 | 59.25 Million USD | 23.58% |
| 2013 | 47.95 Million USD | -17.74% |
| 2012 | 58.29 Million USD | -15.8% |
| 2011 | 69.23 Million USD | -28.37% |
| 2010 | 96.65 Million USD | 15.36% |
| 2009 | 83.78 Million USD | 0.07% |
| 2008 | 83.72 Million USD | -19.12% |
| 2007 | 103.51 Million USD | 94.61% |
| 2006 | 53.19 Million USD | 94.64% |
| 2005 | 27.32 Million USD | 23.72% |
| 2004 | 22.08 Million USD | 54.1% |
| 2003 | 14.33 Million USD | -21.8% |
| 2002 | 18.32 Million USD | 13.54% |
| 2001 | 16.14 Million USD | 22.78% |
| 2000 | 13.14 Million USD | 18.45% |
| 1999 | 11.1 Million USD | -13.95% |
| 1998 | 12.9 Million USD | -7.19% |
| 1997 | 13.9 Million USD | 334.38% |
| 1996 | 3.2 Million USD | 14.29% |
| 1995 | 2.8 Million USD | 12.0% |
| 1994 | 2.5 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 105.85 Million USD | -21.01% |
| 2024 Q2 | 98.51 Million USD | -6.93% |
| 2024 Q3 | 106.16 Million USD | 7.76% |
| 2023 Q3 | 97.52 Million USD | -4.61% |
| 2023 Q1 | 96.25 Million USD | -21.97% |
| 2023 Q2 | 102.24 Million USD | 6.22% |
| 2023 FY | 428.8 Million USD | 3.91% |
| 2023 Q4 | 134.01 Million USD | 37.41% |
| 2022 FY | 412.66 Million USD | 25.96% |
| 2022 Q1 | 99.64 Million USD | 0.73% |
| 2022 Q2 | 100 Million USD | 0.37% |
| 2022 Q3 | 89.65 Million USD | -10.35% |
| 2022 Q4 | 123.36 Million USD | 37.59% |
| 2021 Q4 | 98.91 Million USD | 16.42% |
| 2021 FY | 327.62 Million USD | 71.63% |
| 2021 Q1 | 64.51 Million USD | 14.51% |
| 2021 Q2 | 79.19 Million USD | 22.76% |
| 2021 Q3 | 84.96 Million USD | 7.28% |
| 2020 FY | 190.89 Million USD | 32.39% |
| 2020 Q1 | 45.73 Million USD | 22.73% |
| 2020 Q2 | 41.38 Million USD | -9.51% |
| 2020 Q3 | 47.44 Million USD | 14.64% |
| 2020 Q4 | 56.34 Million USD | 18.76% |
| 2019 Q4 | 37.26 Million USD | 1.11% |
| 2019 Q3 | 36.85 Million USD | 1.42% |
| 2019 Q1 | 33.73 Million USD | 20.81% |
| 2019 Q2 | 36.34 Million USD | 7.73% |
| 2019 FY | 144.18 Million USD | 26.04% |
| 2018 Q2 | 30.5 Million USD | 17.09% |
| 2018 FY | 114.4 Million USD | 41.42% |
| 2018 Q1 | 26.05 Million USD | 20.48% |
| 2018 Q3 | 29.92 Million USD | -1.88% |
| 2018 Q4 | 27.92 Million USD | -6.71% |
| 2017 Q3 | 20.85 Million USD | 12.15% |
| 2017 FY | 80.89 Million USD | 11.95% |
| 2017 Q1 | 19.82 Million USD | 34.71% |
| 2017 Q4 | 21.62 Million USD | 3.69% |
| 2017 Q2 | 18.59 Million USD | -6.23% |
| 2016 Q1 | 23.79 Million USD | 9.29% |
| 2016 Q4 | 14.71 Million USD | -12.7% |
| 2016 FY | 72.26 Million USD | -15.78% |
| 2016 Q3 | 16.86 Million USD | -0.17% |
| 2016 Q2 | 16.89 Million USD | -29.01% |
| 2015 Q4 | 21.76 Million USD | -4.52% |
| 2015 Q2 | 20.05 Million USD | -5.3% |
| 2015 Q1 | 21.18 Million USD | 3.03% |
| 2015 FY | 85.8 Million USD | 44.8% |
| 2015 Q3 | 22.79 Million USD | 13.66% |
| 2014 FY | 59.25 Million USD | 23.58% |
| 2014 Q4 | 20.55 Million USD | 38.46% |
| 2014 Q3 | 14.84 Million USD | 13.52% |
| 2014 Q2 | 13.08 Million USD | 21.44% |
| 2014 Q1 | 10.77 Million USD | -36.21% |
| 2013 Q1 | 8.79 Million USD | -32.46% |
| 2013 Q3 | 9.31 Million USD | -28.13% |
| 2013 Q4 | 16.88 Million USD | 81.28% |
| 2013 FY | 47.95 Million USD | -17.74% |
| 2013 Q2 | 12.95 Million USD | 47.38% |
| 2012 FY | 58.29 Million USD | -15.8% |
| 2012 Q2 | 14.38 Million USD | -16.47% |
| 2012 Q3 | 13.77 Million USD | -4.23% |
| 2012 Q4 | 13.01 Million USD | -5.5% |
| 2012 Q1 | 17.22 Million USD | 5.88% |
| 2011 Q1 | 16.93 Million USD | -37.29% |
| 2011 Q2 | 17.97 Million USD | 6.17% |
| 2011 Q3 | 18.05 Million USD | 0.42% |
| 2011 Q4 | 16.26 Million USD | -9.9% |
| 2011 FY | 69.23 Million USD | -28.37% |
| 2010 Q4 | 27 Million USD | 17.45% |
| 2010 FY | 96.65 Million USD | 15.36% |
| 2010 Q3 | 22.99 Million USD | 28.11% |
| 2010 Q1 | 28.71 Million USD | -18.58% |
| 2010 Q2 | 17.94 Million USD | -37.5% |
| 2009 Q3 | 21.24 Million USD | 57.07% |
| 2009 Q1 | 13.74 Million USD | -43.75% |
| 2009 FY | 83.78 Million USD | 0.07% |
| 2009 Q4 | 35.26 Million USD | 65.99% |
| 2009 Q2 | 13.52 Million USD | -1.6% |
| 2008 FY | 83.72 Million USD | -19.12% |
| 2008 Q4 | 24.43 Million USD | 32.32% |
| 2008 Q3 | 18.46 Million USD | 15.14% |
| 2008 Q2 | 16.03 Million USD | -35.28% |
| 2008 Q1 | 24.78 Million USD | -21.57% |
| 2007 Q3 | 32.32 Million USD | 53.74% |
| 2007 Q2 | 21.02 Million USD | 108.18% |
| 2007 Q1 | 10.09 Million USD | -21.28% |
| 2007 FY | 103.51 Million USD | 94.61% |
| 2007 Q4 | 31.59 Million USD | -2.24% |
| 2006 Q2 | 12.57 Million USD | 31.83% |
| 2006 Q1 | 9.53 Million USD | 27.03% |
| 2006 FY | 53.19 Million USD | 94.64% |
| 2006 Q4 | 12.82 Million USD | -29.7% |
| 2006 Q3 | 18.24 Million USD | 45.13% |
| 2005 Q4 | 7.5 Million USD | -5.66% |
| 2005 Q3 | 7.95 Million USD | 32.87% |
| 2005 Q2 | 5.99 Million USD | 2.03% |
| 2005 FY | 27.32 Million USD | 23.72% |
| 2005 Q1 | 5.87 Million USD | 4.73% |
| 2004 Q3 | 5.56 Million USD | 5.54% |
| 2004 Q2 | 5.27 Million USD | -6.54% |
| 2004 Q4 | 5.6 Million USD | 0.71% |
| 2004 FY | 22.08 Million USD | 54.1% |
| 2004 Q1 | 5.64 Million USD | 38.04% |
| 2003 Q3 | 3.63 Million USD | 3.21% |
| 2003 Q4 | 4.08 Million USD | 12.59% |
| 2003 Q2 | 3.51 Million USD | 13.63% |
| 2003 Q1 | 3.09 Million USD | -0.07% |
| 2003 FY | 14.33 Million USD | -21.8% |
| 2002 FY | 18.32 Million USD | 13.54% |
| 2002 Q4 | 3.09 Million USD | -19.04% |
| 2002 Q3 | 3.82 Million USD | -27.08% |
| 2002 Q2 | 5.24 Million USD | -14.74% |
| 2002 Q1 | 6.15 Million USD | 2.16% |
| 2001 Q3 | 3.51 Million USD | -1.68% |
| 2001 FY | 16.14 Million USD | 22.78% |
| 2001 Q1 | 3.26 Million USD | -2.44% |
| 2001 Q2 | 3.57 Million USD | 9.48% |
| 2001 Q4 | 6.02 Million USD | 71.22% |
| 2000 Q3 | 2.93 Million USD | -21.8% |
| 2000 FY | 13.14 Million USD | 18.45% |
| 2000 Q4 | 3.35 Million USD | 14.32% |
| 2000 Q2 | 3.74 Million USD | 6.51% |
| 2000 Q1 | 3.51 Million USD | 40.75% |
| 1999 Q4 | 2.5 Million USD | -7.41% |
| 1999 FY | 11.1 Million USD | -13.95% |
| 1999 Q3 | 2.7 Million USD | -6.9% |
| 1999 Q2 | 2.9 Million USD | -6.45% |
| 1999 Q1 | 3.1 Million USD | 34.78% |
| 1998 Q1 | 3.4 Million USD | -2.86% |
| 1998 Q4 | 2.3 Million USD | -37.84% |
| 1998 Q3 | 3.7 Million USD | 2.78% |
| 1998 Q2 | 3.6 Million USD | 5.88% |
| 1998 FY | 12.9 Million USD | -7.19% |
| 1997 Q1 | 3.7 Million USD | 175.51% |
| 1997 FY | 13.9 Million USD | 334.38% |
| 1997 Q4 | 3.5 Million USD | 12.9% |
| 1997 Q3 | 3.1 Million USD | -16.22% |
| 1997 Q2 | 3.7 Million USD | 0.0% |
| 1996 Q2 | 3.2 Million USD | 52.38% |
| 1996 Q1 | 2.1 Million USD | 146.67% |
| 1996 FY | 3.2 Million USD | 14.29% |
| 1996 Q4 | -4.9 Million USD | -275.0% |
| 1996 Q3 | 2.8 Million USD | -12.5% |
| 1995 Q1 | 3.3 Million USD | 560.0% |
| 1995 FY | 2.8 Million USD | 12.0% |
| 1995 Q3 | 2.3 Million USD | 21.05% |
| 1995 Q4 | -4.5 Million USD | -295.65% |
| 1995 Q2 | 1.9 Million USD | -42.42% |
| 1994 Q1 | 700 Thousand USD | 0.0% |
| 1994 Q3 | 600 Thousand USD | -25.0% |
| 1994 Q4 | 500 Thousand USD | -16.67% |
| 1994 FY | 2.5 Million USD | 0.0% |
| 1994 Q2 | 800 Thousand USD | 14.29% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | -56.464% |
| Alkermes plc | 996.24 Million USD | 56.774% |
| Agenus Inc. | 78.18 Million USD | -450.81% |
| Aptorum Group Limited | 10.56 Thousand USD | -4075614.556% |
| Ardelyx, Inc. | 169.93 Million USD | -153.412% |
| Dyadic International, Inc. | 9.15 Million USD | -4605.062% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -1835.2% |
| Lantern Pharma Inc. | 17.87 Million USD | -2308.828% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -6296.963% |
| Novavax, Inc. | 779.12 Million USD | 44.728% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -431.248% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -423.918% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -2117.677% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -1354.57% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -710.595% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -13.179% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1671.699% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -1037.183% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -1299.5% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -408.334% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -2366.861% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -155.67% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -1216.338% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -169.509% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 76.076% |
| AlloVir, Inc. | 180.93 Million USD | -138.011% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 3.387% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -1350.846% |
| Bicycle Therapeutics plc | 216.92 Million USD | -98.523% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -150.515% |
| ChromaDex Corporation | 56.37 Million USD | -663.831% |
| Chimerix, Inc. | 93.38 Million USD | -361.125% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -2995.982% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -186.071% |
| CRISPR Therapeutics AG | 463.49 Million USD | 7.088% |
| Precision BioSciences, Inc. | 92.46 Million USD | -365.743% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -69.514% |
| Fortress Biotech, Inc. | 200.19 Million USD | -115.11% |
| Fortress Biotech, Inc. | 200.19 Million USD | -115.11% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -1215.092% |
| ImmuCell Corporation | 9.61 Million USD | -4377.735% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -172.878% |
| Immix Biopharma, Inc. | 16.14 Million USD | -2567.97% |
| Incyte Corporation | 1.19 Billion USD | 63.827% |
| Innoviva, Inc. | 132.15 Million USD | -225.862% |
| IO Biotech, Inc. | 91.44 Million USD | -370.938% |
| Jaguar Health, Inc. | 42.01 Million USD | -924.967% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -154.4% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -410.703% |
| ContextLogic Inc. | 387 Million USD | -11.276% |
| MiMedx Group, Inc. | 229.72 Million USD | -87.457% |
| MEI Pharma, Inc. | 34.78 Million USD | -1138.005% |
| NextCure, Inc. | 67.63 Million USD | -536.693% |
| Onconetix, Inc. | 34.9 Million USD | -1133.663% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -3278.629% |
| Opthea Limited | 191.96 Million USD | -124.33% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -15550.616% |
| Vaxcyte, Inc. | 468.04 Million USD | 7.991% |
| PDS Biotechnology Corporation | 43.04 Million USD | -900.436% |
| Precigen, Inc. | 84.18 Million USD | -411.564% |
| Pharming Group N.V. | 225.49 Million USD | -90.979% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -156.598% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -493.446% |
| PureTech Health plc | 144.59 Million USD | -197.821% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -230.593% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -75.658% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1671.699% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -88.316% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -1295.509% |
| Acelyrin, Inc. | 422.06 Million USD | -2.032% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -3339747.991% |
| Summit Therapeutics Inc. | 87.68 Million USD | -391.116% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -1061.882% |
| Senti Biosciences, Inc. | 94.7 Million USD | -354.717% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -248.547% |
| Elevation Oncology, Inc. | 45.44 Million USD | -847.607% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -1361.332% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -10824.271% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -225.81% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -1163.43% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -4995.728% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -137.528% |
| Seer, Inc. | 110.49 Million USD | -289.755% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -510.024% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -360.686% |
| ESSA Pharma Inc. | 32.13 Million USD | -1240.134% |
| GlycoMimetics, Inc. | 39.28 Million USD | -996.186% |
| GT Biopharma, Inc. | 13.57 Million USD | -3072.068% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -95.897% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -114.126% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -65.998% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -658.717% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -696.302% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -4233.421% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | -6.709% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -2175.028% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -749.506% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -65.848% |
| Aptose Biosciences Inc. | 52.35 Million USD | -722.523% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -2888.403% |
| Soligenix, Inc. | 7.79 Million USD | -5424.389% |
| Century Therapeutics, Inc. | 56.07 Million USD | -668.026% |
| Kura Oncology, Inc. | 165.8 Million USD | -159.728% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -276.082% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -5076.584% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -17253.048% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -299.859% |
| Autolus Therapeutics plc | 196.72 Million USD | -118.903% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -408.688% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -269.797% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -2121.741% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -33.84% |
| GRI Bio, Inc. | 11.33 Million USD | -3700.883% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -6003.433% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -228.249% |
| IGM Biosciences, Inc. | 265.59 Million USD | -62.144% |
| INmune Bio, Inc. | 29.89 Million USD | -1340.46% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -149.568% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -968.206% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -2594.976% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -2635.689% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -593.484% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -300.513% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -56.203% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -42.856% |
| Verastem, Inc. | 92.08 Million USD | -367.66% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -2300.58% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -131.87% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -254.708% |
| Histogen Inc. | 14.27 Million USD | -2917.377% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -2583.426% |
| Surrozen, Inc. | 18.55 Million USD | -2221.509% |
| Organovo Holdings, Inc. | 14.91 Million USD | -2787.295% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -8360.119% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -621.664% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -1579.105% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -816.138% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -5541.934% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -141.748% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -788.871% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -75.769% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -2702.446% |
| Apollomics, Inc. | 54.14 Million USD | -695.419% |
| Amarin Corporation plc | 272.35 Million USD | -58.116% |
| Mesoblast Limited | 5.9 Million USD | -7196.51% |
| Turnstone Biologics Corp. | 78.33 Million USD | -449.72% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -76.404% |
| Synaptogenix, Inc. | 8.31 Million USD | -5079.788% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -2852.42% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -70.176% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -1192.046% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -4776.328% |
| Exelixis, Inc. | 1.58 Billion USD | 72.861% |
| Better Therapeutics, Inc. | 38.26 Million USD | -1025.503% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -85.581% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 49.645% |
| NLS Pharmaceutics AG | 11.8 Million USD | -3547.308% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -5254.949% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -1335.802% |
| Gritstone bio, Inc. | 148.37 Million USD | -190.24% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -525.376% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -2532.239% |
| Avid Bioservices, Inc. | 25.99 Million USD | -1556.563% |
| Insmed Incorporated | 949.26 Million USD | 54.634% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -2644.715% |
| MediWound Ltd. | 18.86 Million USD | -2182.383% |
| OmniAb, Inc. | 83.89 Million USD | -413.308% |
| Alector, Inc. | 248.8 Million USD | -73.085% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -83.792% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -724.176% |
| Zai Lab Limited | 547.47 Million USD | 21.341% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -8.023% |
| Aura Biosciences, Inc. | 84.99 Million USD | -406.689% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -74.251% |
| Immunic, Inc. | 99.22 Million USD | -334.012% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -170.822% |
| Veracyte, Inc. | 357.93 Million USD | -20.313% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 95.223% |
| FibroGen, Inc. | 398.11 Million USD | -8.17% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -2930.542% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -6152.081% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -5943.449% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 86.772% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -1564.438% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -36.045% |
| TG Therapeutics, Inc. | 198.47 Million USD | -116.974% |
| Galecto, Inc. | 35.62 Million USD | -1108.746% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -958.37% |
| Fortrea Holdings Inc. | 457.3 Million USD | 5.83% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -693.397% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -1391.239% |
| XBiotech Inc. | 37.51 Million USD | -1048.067% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -525.376% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -1985.525% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -203.137% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -334.661% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -288.959% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 55.06% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -1392.945% |
| Vaxxinity, Inc. | 56.05 Million USD | -668.3% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -1830.401% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -288.429% |
| NexImmune, Inc. | 28.16 Million USD | -1428.854% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -7686.007% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -2306.817% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 84.704% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -1591.504% |
| Scopus BioPharma Inc. | 11.71 Million USD | -3576.01% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -238.921% |
| Ainos, Inc. | 12.95 Million USD | -3224.722% |
| Pluri Inc. | 22.48 Million USD | -1815.658% |
| Prothena Corporation plc | 282.4 Million USD | -52.49% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -115.296% |
| Celularity Inc. | 215.05 Million USD | -100.244% |
| Rallybio Corporation | 78.93 Million USD | -445.584% |
| Cue Biopharma, Inc. | 19.54 Million USD | -2103.664% |
| MeiraGTx Holdings plc | 151.07 Million USD | -185.045% |
| Omeros Corporation | 94.75 Million USD | -354.497% |
| Humacyte, Inc. | 23.49 Million USD | -1732.745% |
| Immunocore Holdings plc | 308.04 Million USD | -39.8% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -12603.245% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -395.758% |
| Blueprint Medicines Corporation | 722.86 Million USD | 40.426% |
| CalciMedica, Inc. | 21.81 Million USD | -1873.874% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -476.802% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -168.245% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -151.403% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -46.009% |
| Pulmatrix, Inc. | 22.03 Million USD | -1854.079% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -1145.524% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -384.595% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 21.924% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -493.569% |
| Cytokinetics, Incorporated | 173.61 Million USD | -148.047% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -1151.169% |
| Nutriband Inc. | 5.73 Million USD | -7410.249% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -887.412% |
| Vor Biopharma Inc. | 126.03 Million USD | -241.68% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 63.787% |
| Evogene Ltd. | 27.79 Million USD | -1449.622% |
| ProKidney Corp. | 151.52 Million USD | -184.21% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -480.573% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -5498.368% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 29.889% |
| CorMedix Inc. | 48.95 Million USD | -779.615% |
| BioLineRx Ltd. | 50.8 Million USD | -747.683% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -185.76% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -1031.12% |
| Atai Life Sciences N.V. | 125.78 Million USD | -242.362% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -427.491% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -428.983% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -70.515% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -1215.333% |
| MediciNova, Inc. | 10.9 Million USD | -3850.73% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -234.296% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -5832.069% |
| GeoVax Labs, Inc. | 6.02 Million USD | -7050.907% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 9.598% |
| Biomea Fusion, Inc. | 126.13 Million USD | -241.412% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 67.173% |
| Mereo BioPharma Group plc | 35.84 Million USD | -1101.495% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -125.361% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -87.272% |
| Absci Corporation | 73.66 Million USD | -484.584% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1461.308% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -222.359% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -77.831% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -64.336% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -107.044% |
| Allakos Inc. | 196.05 Million USD | -119.652% |
| Imunon, Inc. | 20.31 Million USD | -2020.29% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -279.522% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -16.827% |
| BioAtla, Inc. | 129.68 Million USD | -232.061% |
| NLS Pharmaceutics AG | 11.8 Million USD | -3547.308% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -2618.172% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -407.125% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -931.275% |
| XOMA Corporation | 46.46 Million USD | -826.845% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -287.367% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -202.282% |
| aTyr Pharma, Inc. | 12.97 Million USD | -3217.975% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -315.451% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -149.112% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -69.035% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -1051.198% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -5135.863% |
| Akari Therapeutics, Plc | 16.8 Million USD | -2462.418% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -18837.805% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -43.874% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -6300.019% |
| UroGen Pharma Ltd. | 138.88 Million USD | -210.063% |
| Sutro Biopharma, Inc. | 243 Million USD | -77.212% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -5819.758% |
| Orgenesis Inc. | 45.75 Million USD | -841.146% |
| Entera Bio Ltd. | 8.86 Million USD | -4760.497% |
| GH Research PLC | 41.22 Million USD | -944.685% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -1575.121% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -418.512% |
| Xencor, Inc. | 306.97 Million USD | -40.284% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -8628.707% |
| Replimune Group, Inc. | 234.77 Million USD | -83.428% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -2001.72% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -124.53% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -6300.019% |
| Portage Biotech Inc. | 18.19 Million USD | -2266.284% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -5832.069% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -310.286% |
| OncoCyte Corporation | 25.63 Million USD | -1579.76% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -6964.76% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -3658.73% |
| Purple Biotech Ltd. | -22.46 Million USD | 2016.767% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -2513.107% |
| scPharmaceuticals Inc. | 65.17 Million USD | -560.714% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -4994.682% |
| HilleVax, Inc. | 133.34 Million USD | -222.952% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -4087.069% |
| Tharimmune, Inc. | 9.45 Million USD | -4454.521% |
| Genprex, Inc. | 31.06 Million USD | -1286.453% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -129.643% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -1272.47% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -56192.81% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -7806.121% |
| OKYO Pharma Limited | 8243.57 USD | -5223850.303% |
| Savara Inc. | 15.74 Million USD | -2635.091% |
| Curis, Inc. | 58.35 Million USD | -637.966% |
| Daré Bioscience, Inc. | 33.6 Million USD | -1181.308% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -8356.377% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -5671.88% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -1493.664% |
| BeiGene, Ltd. | 3.28 Billion USD | 86.897% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -2059.755% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 13.659% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -180.27% |
| Erasca, Inc. | 141.52 Million USD | -204.285% |
| bluebird bio, Inc. | 240.23 Million USD | -79.26% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -9412.756% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 75.34% |
| DBV Technologies S.A. | 92.16 Million USD | -367.274% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -9412.756% |
| Moderna, Inc. | 6.39 Billion USD | 93.265% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -910.678% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -2897.633% |
| Molecular Templates, Inc. | 63.09 Million USD | -582.57% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -545.628% |
| Travere Therapeutics, Inc. | 472 Million USD | 8.763% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -200.493% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -593.663% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -891.938% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -106.909% |
| MacroGenics, Inc. | 217.21 Million USD | -98.255% |
| RenovoRx, Inc. | 11.39 Million USD | -3678.87% |
| Adicet Bio, Inc. | 152.03 Million USD | -183.245% |
| Prime Medicine, Inc. | 186.63 Million USD | -130.734% |
| Aditxt, Inc. | 25.95 Million USD | -1559.45% |
| Adagene Inc. | 41.83 Million USD | -929.467% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -5791.029% |
| Quantum-Si incorporated | 111.65 Million USD | -285.674% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -150.591% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -2854.087% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -1102.166% |
| SciSparc Ltd. | 9.01 Million USD | -4679.048% |
| Vericel Corporation | 142.04 Million USD | -203.182% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -4874.665% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -1765.163% |
| Generation Bio Co. | 144.46 Million USD | -198.089% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -418.656% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -398.08% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -45.624% |
| Invivyd, Inc. | 205.75 Million USD | -109.297% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -496.793% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -4491.777% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -472.249% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -4086.254% |
| 2seventy bio, Inc. | 289.88 Million USD | -48.554% |
| ADMA Biologics, Inc. | 66.58 Million USD | -546.743% |
| Clene Inc. | 41.07 Million USD | -948.475% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -3262.304% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -685.897% |
| GeoVax Labs, Inc. | 6.02 Million USD | -7050.907% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -22.324% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -1072.383% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -1176.803% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -315.267% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -1221.427% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -152.904% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 43.907% |
| Evaxion Biotech A/S | 22.27 Million USD | -1833.722% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -217.712% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -83.343% |
| Trevena, Inc. | 38.41 Million USD | -1021.079% |
| Surrozen, Inc. | 18.55 Million USD | -2221.509% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -438.67% |
| Cingulate Inc. | 22.75 Million USD | -1792.159% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 5847.998% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -864.112% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -5130.059% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -319.899% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 42.892% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -593.753% |
| Clearmind Medicine Inc. | 8.74 Million USD | -4826.47% |
| Kronos Bio, Inc. | 128.11 Million USD | -236.128% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -412.228% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -14582.653% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -327.108% |
| Statera Biopharma, Inc. | 28.82 Million USD | -1393.747% |
| ImmunityBio, Inc. | 362.87 Million USD | -18.675% |
| Korro Bio, Inc. | 84.53 Million USD | -409.428% |
| Kineta, Inc. | 21.15 Million USD | -1935.545% |
| BioVie Inc. | 31.95 Million USD | -1247.847% |
| Codexis, Inc. | 66.51 Million USD | -547.404% |
| Celularity Inc. | 215.05 Million USD | -100.244% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -90.027% |
| Celcuity Inc. | 66.23 Million USD | -550.216% |
| Virax Biolabs Group Limited | 6.54 Million USD | -6477.606% |
| Cibus, Inc. | 320.3 Million USD | -34.447% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -901.488% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -1172.426% |
| IN8bio, Inc. | 30.33 Million USD | -1319.521% |
| Kodiak Sciences Inc. | 277.32 Million USD | -55.286% |
| Annexon, Inc. | 143.72 Million USD | -199.632% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -237.516% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -1779.785% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -67187.5% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 44.76% |
| Eyenovia, Inc. | 25.4 Million USD | -1595.003% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -206.909% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -7642.539% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -444.198% |
| Arcellx, Inc. | 200.19 Million USD | -115.106% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -838.214% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -98.992% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -4224.997% |
| Moolec Science SA | 52.75 Million USD | -716.37% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -604.374% |
| Geron Corporation | 70.44 Million USD | -511.349% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -825.312% |
| Royalty Pharma plc | 862.4 Million USD | 50.065% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -357.777% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -4516.704% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -1803.084% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -107.226% |
| Humacyte, Inc. | 23.49 Million USD | -1732.745% |
| Structure Therapeutics Inc. | 102.77 Million USD | -319.012% |
| 89bio, Inc. | 151.2 Million USD | -184.807% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -437.413% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -2861.761% |
| Genelux Corporation | 24.33 Million USD | -1669.632% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -1169.463% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -149.113% |
| Notable Labs, Ltd. | 14.77 Million USD | -2815.64% |
| Liquidia Corporation | 87.98 Million USD | -389.453% |
| Mustang Bio, Inc. | 48.5 Million USD | -787.899% |
| Immunovant, Inc. | 282.7 Million USD | -52.326% |
| Quantum-Si incorporated | 111.65 Million USD | -285.674% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -1810.22% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -1924.921% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -322.146% |
| Acasti Pharma Inc. | 11.3 Million USD | -3710.636% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -1778.792% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -2594.976% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -825.272% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -37855.896% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -2610.815% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -1376.97% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -940.595% |
| PepGen Inc. | 84.76 Million USD | -408.034% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -1353.343% |
| United Therapeutics Corporation | 885.1 Million USD | 51.346% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -1780.77% |
| Solid Biosciences Inc. | 104.31 Million USD | -312.827% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -1215.914% |
| Immuneering Corporation | 58.41 Million USD | -637.235% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -8360.119% |
| Silo Pharma, Inc. | 3.92 Million USD | -10880.515% |
| Belite Bio, Inc | 31.66 Million USD | -1259.859% |
| XOMA Corporation | 46.46 Million USD | -826.845% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -537.513% |
| Bionomics Limited | 17.89 Billion USD | 97.593% |
| Apogee Therapeutics, Inc. | 93 Million USD | -363.039% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1306.951% |
| uniQure N.V. | 285.08 Million USD | -51.056% |
| Cassava Sciences, Inc. | 105.95 Million USD | -306.429% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -5791.029% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -121.743% |
| Forte Biosciences, Inc. | 32.47 Million USD | -1225.985% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -5082.967% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -1365.011% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -7642.539% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -2930.542% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -4744.639% |
| Altimmune, Inc. | 30.55 Million USD | -1309.347% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -0.699% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1306.951% |
| Compugen Ltd. | 43.97 Million USD | -879.373% |
| Peak Bio, Inc. | 1249.13 USD | -34475094.736% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -481.004% |
| Benitec Biopharma Inc. | 22.38 Million USD | -1824.046% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -77.08% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -1408.741% |
| Zura Bio Limited | 62.63 Million USD | -587.506% |
| PolyPid Ltd. | 21.04 Million USD | -1946.282% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -2545.859% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -1408.741% |
| Instil Bio, Inc. | 85.78 Million USD | -401.999% |
| argenx SE | 1.53 Billion USD | 71.918% |
| Immunome, Inc. | 122.82 Million USD | -250.627% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -788.412% |
| Verona Pharma plc | 67.15 Million USD | -541.298% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -1563.666% |
| Shattuck Labs, Inc. | 93.61 Million USD | -360.017% |
| CervoMed Inc. | 14.95 Million USD | -2779.039% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -509.083% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -4940.262% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -744.392% |
| Moolec Science SA | 52.75 Million USD | -716.37% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -2518.121% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -224.876% |
| AnaptysBio, Inc. | 181.56 Million USD | -137.178% |
| Design Therapeutics, Inc. | 78.19 Million USD | -450.761% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -394.755% |
| NeurAxis, Inc. | 8.82 Million USD | -4781.876% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -3321.851% |
| Lumos Pharma, Inc. | 38.66 Million USD | -1013.772% |
| Achilles Therapeutics plc | 75.25 Million USD | -472.241% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -1563.666% |
| 180 Life Sciences Corp. | 13.47 Million USD | -3095.251% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -1524.907% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -14582.653% |
| Nutriband Inc. | 5.73 Million USD | -7410.249% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -288.734% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -673.795% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -746.4% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -551.508% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -695.668% |
| Palisade Bio, Inc. | 13.32 Million USD | -3133.033% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -848.358% |
| Beam Therapeutics Inc. | 554.19 Million USD | 22.294% |
| Neurogene Inc. | 55.58 Million USD | -674.769% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -73.303% |
| AEON Biopharma, Inc. | 48.42 Million USD | -789.219% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -345.29% |
| Sesen Bio, Inc. | 78.38 Million USD | -449.419% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -415.557% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -3321.336% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 4.513% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -389.976% |
| Athira Pharma, Inc. | 125.46 Million USD | -243.232% |
| Vaccinex, Inc. | 23.45 Million USD | -1736.026% |
| HCW Biologics Inc. | 21.02 Million USD | -1947.983% |
| XOMA Corporation | 46.46 Million USD | -826.845% |
| Nektar Therapeutics | 190.9 Million USD | -125.581% |
| Arvinas, Inc. | 480 Million USD | 10.283% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -18837.805% |
| Merus N.V. | 200.49 Million USD | -114.789% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -316.661% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -1143.905% |
| Rezolute, Inc. | 70.38 Million USD | -511.818% |
| Clene Inc. | 41.07 Million USD | -948.475% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -2529.305% |
| BeyondSpring Inc. | 24.86 Million USD | -1631.912% |
| Synlogic, Inc. | 58.53 Million USD | -635.734% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -2306.886% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -9486.821% |
| Peak Bio, Inc. | 1249.13 USD | -34475094.736% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -612.438% |
| Krystal Biotech, Inc. | 160.42 Million USD | -168.435% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -59.124% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -23.734% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -19867.228% |
| MannKind Corporation | 125.59 Million USD | -242.874% |
| Ikena Oncology, Inc. | 84.57 Million USD | -409.169% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -4363.978% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -380.62% |
| Gossamer Bio, Inc. | 183.75 Million USD | -134.35% |
| CohBar, Inc. | 12.38 Million USD | -3376.184% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -748.987% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1461.308% |
| Legend Biotech Corporation | 583.14 Million USD | 26.152% |
| Mural Oncology plc | 192.07 Million USD | -124.209% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -541.339% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -2567.283% |
| Disc Medicine, Inc. | 91.12 Million USD | -372.582% |
| Champions Oncology, Inc. | 28.11 Million USD | -1431.982% |
| REGENXBIO Inc. | 321.15 Million USD | -34.09% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -7932.479% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -672.365% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -1005.321% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -276.575% |
| Vaxart, Inc. | 90.72 Million USD | -374.66% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -4954.455% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -906.307% |
| Cellectis S.A. | 97.32 Million USD | -342.499% |
| Longeveron Inc. | 21.25 Million USD | -1926.541% |
| Repare Therapeutics Inc. | 167.35 Million USD | -157.318% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 68.354% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -469.291% |
| Revolution Medicines, Inc. | 498.76 Million USD | 13.659% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -6373.842% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -879.752% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -477.343% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -518.425% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -3793.671% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 90.981% |
| Denali Therapeutics Inc. | 527.23 Million USD | 18.32% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -4874.665% |
| Veru Inc. | 101.34 Million USD | -324.912% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -1739.792% |
| Cingulate Inc. | 22.75 Million USD | -1792.159% |
| Passage Bio, Inc. | 108.38 Million USD | -297.31% |
| Context Therapeutics Inc. | 25.07 Million USD | -1617.571% |
| Exicure, Inc. | 14.07 Million USD | -2959.392% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -108.984% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -894.527% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -4592.453% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -70.562% |
| Nuvalent, Inc. | 149.49 Million USD | -188.069% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -5238.357% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -315.475% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -1907.739% |
| OmniAb, Inc. | 83.89 Million USD | -413.308% |
| Anew Medical, Inc. | 1.3 Million USD | -33004.738% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -1214.369% |
| Lipocine Inc. | 15.08 Million USD | -2755.677% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -528.552% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -465.501% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -968.206% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -274.981% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -1823.874% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 35.159% |
| Ocugen, Inc. | 71.56 Million USD | -501.73% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -358.782% |
| Q32 Bio Inc. | 92.68 Million USD | -364.653% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -1933.815% |
| Alumis Inc. Common Stock | 158.17 Million USD | -172.257% |
| Equillium, Inc. | 50.6 Million USD | -750.966% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -590.062% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -2996.892% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -2182.733% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -817.212% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -297.028% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -3374.941% |
| Dominari Holdings Inc. | 23.83 Million USD | -1706.755% |
| Edesa Biotech, Inc. | 9.22 Million USD | -4569.319% |
| vTv Therapeutics Inc. | 11.9 Million USD | -3516.696% |
| Bio-Techne Corporation | 563.03 Million USD | 23.515% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -5.341% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -60.235% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -225.559% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -2888.273% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -163.073% |
| Nkarta, Inc. | 131.65 Million USD | -227.11% |
| BioCardia, Inc. | 12.12 Million USD | -3452.842% |
| Iterum Therapeutics plc | 47.46 Million USD | -807.222% |